Guangdong Zhongsheng Pharmaceutical Co., Ltd.
002317
주식 순위
#4568
Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical... Guangdong Zhongsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company actively involved in the entire lifecycle of drug development, from research and development to manufacturing and commercialization. Its product portfolio encompasses both traditional Chinese medicines (TCM) and modern chemical pharmaceuticals. The company's robust research and development initiatives are directed towards creating solutions for a wide array of health conditions, specifically targeting ophthalmological, cardiovascular, cerebrovascular, respiratory, digestive, diabetic, oncological, and age-related degenerative diseases. Established in 1979, the company maintains its primary operations from its headquarters in Dongguan, China.
주가
$3.89
시가총액
$3.30B
변동 (1일)
-3.14%
변동 (1년)
43.11%
국가
CN
거래 Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317)
카테고리
Healthcare
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317)의 수익
Jun 2026 기준 수익 TTM: $30.61M
Guangdong Zhongsheng Pharmaceutical Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $30.61M입니다. 2024년에 회사는 $-46.02M의 수익을 올렸으며 이는 2023년의 수익 $40.07M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Guangdong Zhongsheng Pharmaceutical Co., Ltd.의 수익 기록 (2006 ~ 2026)
연말 수익
| 연도 | 수익 | 변화 |
|---|---|---|
| 2026 (TTM) | $30.61M | -27.78% |
| 2025 | $42.39M | -192.12% |
| 2024 | $-46.02M | -214.83% |
| 2023 | $40.07M | -24.95% |
| 2022 | $53.39M | 9.66% |
| 2021 | $48.69M | -192.13% |
| 2020 | $-52.85M | -197.14% |
| 2019 | $54.41M | -25.14% |
| 2018 | $72.68M | -3.83% |
| 2017 | $75.58M | 8.55% |
| 2016 | $69.62M | 32.24% |
| 2015 | $52.65M | 31.36% |
| 2014 | $40.08M | 11.54% |
| 2013 | $35.94M | 5.30% |
| 2012 | $34.13M | 22.83% |
| 2011 | $27.78M | 19.74% |
| 2010 | $23.20M | 38.06% |
| 2009 | $16.81M | 34.21% |
| 2008 | $12.52M | 76.32% |
| 2007 | $7.10M | 52.00% |
| 2006 | $4.67M | 0.00% |
유사 기업 또는 경쟁사의 수익
| 회사 | 수익 | 수익 차이 | 국가 |
|---|---|---|---|
| $3.62B | 11,717.83% |
DE
|
|
| $3.40B | 11,022.45% |
DE
|
|
| $1.72B | 5,530.23% |
JP
|
|
| $930.30M | 2,938.85% |
CH
|
|
| $1.76B | 5,663.95% |
IN
|
